drugset
drugset / Trial / NCT03217604

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects

NCT03217604 ↗

Phase 1 Completed 17 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of PF-06852231 after first-time administration to healthy adult subjects. The safety, tolerability, and pharmacokinetics of an active metabolite (PF-06892787) will also be evaluated in this study.

Timeline

Start
2017-07-13
Primary completion
2018-02-01
Completion
2018-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Emraclidine Small molecule — Oral

Indications

No indication recorded.